drugset / Trial / NCT00849329
A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will characterize the effect of elevated gastric pH mediated by the proton-pump inhibitor, esomeprazole, on the relative bioavailability of lapatinib in subjects with metastatic ErbB2 positive breast cancer.
Timeline
- Start
- 2009-03-10
- Primary completion
- 2009-11-24
- Completion
- 2009-11-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Esomeprazole | Small molecule | 40 mg | — |
| Subject | Lapatinib | Small molecule | 1250 mg | Oral |